Arrowhead (NASDAQ: ARWR) CMO sells 10,000 pre-planned shares

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $75.00 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Hamilton directly holds 226,958 shares, including shares underlying Restricted Stock Units, some of which remain subject to vesting conditions.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($750,000)

Net Sell 1 txn

Insider Hamilton James C

Role Chief Medical Officer

Sold 10,000 shs ($750K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$75.00	$750K

Holdings After Transaction: Common Stock — 226,958 shares (Direct, null)

Footnotes (1)

1. Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $75.00 per share Post-transaction holdings: 226,958 shares +1 more

4 metrics

Shares sold 10,000 shares Open-market sale of common stock

Weighted average sale price $75.00 per share Sale executed in multiple transactions

Post-transaction holdings 226,958 shares Shares directly held after the sale

Price range of trades $75.00–$75.13 per share Range of prices for individual sale transactions

Key Terms

Rule 10b5-1 trading plan, weighted average price, Restricted Stock Units

3 terms

Rule 10b5-1 trading plan regulatory

"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported on Column 4 is the weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Restricted Stock Units financial

"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamilton James C

(Last) (First) (Middle)

177 EAST COLORADO BLVD

SUITE 700

(Street)

PASADENA CALIFORNIA 91105

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/23/2026		S(1)		10,000	D	$75(2)	226,958(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

2. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

3. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Remarks:

	/s/James Hamilton	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Arrowhead Pharmaceuticals (ARWR) disclose for James C. Hamilton?

Arrowhead Pharmaceuticals reported that Chief Medical Officer James C. Hamilton sold 10,000 shares of common stock. The open-market sale occurred at a weighted average price of $75.00 per share and was executed under a pre-arranged Rule 10b5-1 trading plan.

At what price did the Arrowhead Pharmaceuticals (ARWR) CMO sell his shares?

The Chief Medical Officer sold 10,000 Arrowhead Pharmaceuticals shares at a weighted average price of $75.00. Individual trades were executed in multiple transactions at prices ranging from $75.00 to $75.13 per share, as disclosed in the Form 4 footnotes.

How many Arrowhead Pharmaceuticals (ARWR) shares does the CMO hold after the sale?

After the reported sale, Chief Medical Officer James C. Hamilton directly holds 226,958 shares of Arrowhead Pharmaceuticals common stock. This figure includes previously reported shares underlying Restricted Stock Units, a portion of which remains subject to specified vesting conditions.

Was the Arrowhead Pharmaceuticals (ARWR) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 states the shares were sold pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged under SEC rules and are designed to allow insiders to sell shares according to a predetermined schedule, independent of day-to-day market developments.

What does the weighted average price mean in the Arrowhead (ARWR) Form 4 filing?

The Form 4 reports a weighted average sale price of $75.00 per share. This means the 10,000 shares were sold in multiple trades at prices between $75.00 and $75.13, and the reported figure reflects the average price across those individual transactions.